Late-breaking phase 3 SENTRY data show selinexor plus ruxolitinib improves spleen volume, survival, and disease markers in myelofibrosis.
Claire Harrison, MD
Advertisement
Claire Harrison, MD, is a professor of hematology at the Guy's and St. Thomas' NHS Foundation Trust in London, England.
Articles by Claire Harrison, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Tec-Dara Demonstrates Superior 3-Year PFS vs Standard Therapy in Functional High-Risk Myeloma: Rahul Banerjee, MD
2
MRD-Guided CLL Treatment Duration: Personalization or Malpractice?
3
Global Hematology Trials Ensure Research Stays Applicable, Flexible, Patient-Centered
4
Blinatumomab Improves Outcomes, Toxicity in High-Risk Pediatric ALL: Martin Schrappe, MD, PhD
5